ChabioTech Receives Approval to Change Clinical Trials Phase 1 and 2a for Degenerative Disc Disease Treatment
[Asia Economy Reporter Minji Lee] Cha Biotech announced on the 15th that the Ministry of Food and Drug Safety approved a change in the clinical phase 1 and 2a trial plan evaluating the safety and efficacy of 'CordSTEM-DD' for chronic low back pain patients caused by degenerative lumbar intervertebral discs.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- "All Major Corporations Could Leave"... Business Community Fears Overseas Factory Relocation Due to Strike Risks
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
